


IN THE CLAIMS

Please amend the claims as follows:

1.-19. (Cancelled)

20 (New): A metalloporphyrin complex-embedding niosome comprising:
a cationized metalloporphyrin complex of formula (I), (II) or (III) and
a niosome-forming substance;
wherein formula (I), (II), and (III) are:



wherein

at least one of R₁ to R₄ is a group selected from an N-lower-alkylpyridyl group, a lower-alkylammoniophenyl group, and an N-lower-alkylimidazolyl group,

R₁₁ to R₁₆ and R₂₁ to R₂₆ are lower alkyl or lower alkoxy groups,

R₁₇ and R₁₈ are groups selected from an N-lower-alkylpyridyl group, a lower-alkylammoniophenyl group, and an N-loweralkylimidazolyl group, and

R₂₇ and R₂₈ are N-alkylammonio groups.

21 (New): The metalloporphyrin complex-embedding niosome of claim 20,
wherein the niosome-forming substance is a nonionic surfactant or a mixture of a nonionic surfactant and a cholesterol or a triacylglycerol.

22 (New): The metalloporphyrin complex-embedding niosome of claim 20, wherein the niosome is endoplasmic reticula with a diameter of 100 nm or less.

23 (New): The metalloporphyrin complex-embedding niosome of claim 20, wherein the niosome-forming substance is a nonionic surfactant or a mixture of a nonionic surfactant and a cholesterol or a triacylglycerol, and
the niosome is endoplasmic reticula with a diameter of 100 nm or less.

24 (New): The metalloporphyrin complex-embedding niosome of claim 20, wherein the cationized metalloporphyrin complex is one or more of metal [5,10,15,20-tetrakis (2-methylpyridyl) porphyrin] (MT2MPyP), metal [5,10,15,20-tetrakis (4-methylpyridyl) porphyrin] (MT4MPyP), or metal [[1,3,5,8-tetramethyl-2,4-divinyl-6,7-di (4-methylpyridylamideethyl)] porphyrin] (MPPIX-DMPyAm),
wherein the metal (M) is iron (Fe), manganese (Mn), cobalt (Co), copper (Cu), molybdenum (Mo), chromium (Cr), or iridium (Ir).

25 (New): The metalloporphyrin complex-embedding niosome of claim 20, wherein the cationized metalloporphyrin complex is one or more of metal [5,10,15,20-tetrakis (2-methylpyridyl) porphyrin] (MT2MPyP), metal [5,10,15,20-tetrakis (4-methylpyridyl) porphyrin] (MT4MPyP), or metal [[1,3,5,8-tetramethyl-2,4-divinyl-6,7-di (4-methylpyridylamideethyl)] porphyrin] (MPPIX-DMPyAm),

wherein the metal (M) is iron (Fe), manganese (Mn), cobalt (Co), copper (Cu), molybdenum (Mo), chromium (Cr), or iridium (Ir), and

the niosome-forming substance is a nonionic surfactant or a mixture of a nonionic surfactant and a cholesterol or a triacylglycerol.

26 (New): The metalloporphyrin complex-embedding niosome of claim 20, wherein the cationized metalloporphyrin complex is one or more of metal [5,10,15,20-tetrakis (2-methylpyridyl) porphyrin] (MT2MPyP), metal [5,10,15,20-tetrakis (4-methylpyridyl) porphyrin] (MT4MPyP), or metal [[1,3,5,8-tetramethyl-2,4-divinyl-6,7-di (4-methylpyridylamideethyl)] porphyrin] (MPPIX-DMPyAm),

wherein the metal (M) is iron (Fe), manganese (Mn), cobalt (Co), copper (Cu), molybdenum (Mo), chromium (Cr), or iridium (Ir), and

the niosome is endoplasmic reticula with a diameter of 100 nm or less.

27 (New): The metalloporphyrin complex-embedding niosome of claim 20, wherein the cationized metalloporphyrin complex is one or more of metal [5,10,15,20-tetrakis (2-methylpyridyl) porphyrin] (MT2MPyP), metal [5,10,15,20-tetrakis (4-methylpyridyl) porphyrin] (MT4MPyP), or metal [[1,3,5,8-tetramethyl-2,4-divinyl-6,7-di (4-methylpyridylamideethyl)] porphyrin] (MPPIX-DMPyAm),

wherein the metal (M) is iron (Fe), manganese (Mn), cobalt (Co), copper (Cu), molybdenum (Mo), chromium (Cr), or iridium (Ir),

the niosome-forming substance is a nonionic surfactant or a mixture of a nonionic surfactant and a cholesterol or a triacylglycerol, and

the niosome is endoplasmic reticula with a diameter of 100 nm or less.

28 (New): The metalloporphyrin complex-embedding niosome of claim 20,
a cationized metalloporphyrin complex and
a niosome-forming substance,
wherein the cationized metalloporphyrin complex is a complex shown by the
following formula (I), (II), or (III),

wherein at least one of R_1 to R_4 is a group selected from an N-lower-alkylpyridyl group, a lower-alkylammoniophenyl group, and an N-lower-alkylimidazolyl group, R_{11} to R_{16} and R_{21} to R_{26} are lower alkyl or lower alkoxy groups, R_{17} and R_{18} are groups selected from an N-lower-alkylpyridyl group, a lower-alkylammoniophenyl group, and an N-loweralkylimidazolyl group, and R_{27} and R_{28} indicate N-alkylammonio groups and one or more of metal [5,10,15,20-tetrakis (2-methylpyridyl) porphyrin] (MT2MPyP), metal [5,10,15,20-tetrakis (4-methylpyridyl) porphyrin] (MT4MPyP), or metal [[1,3,5,8-tetramethyl-2,4-divinyl-6,7-di (4-methylpyridylamideethyl)] porphyrin] (MPPIX-DMPyAm), wherein the metal (M) is iron (Fe), manganese (Mn), cobalt (Co), copper (Cu), molybdenum (Mo), chromium (Cr), or iridium (Ir).

29 (New): A metalloporphyrin complex-embedding niosome comprising
a cationized metalloporphyrin complex and
a niosome-forming substance,
wherein the cationized metalloporphyrin complex is a complex shown by the
following formula (I), (II), or (III),

wherein at least one of R₁ to R₄ is a group selected from an N-lower-alkylpyridyl group, a lower-alkylammoniophenyl group, and an N-lower-alkylimidazolyl group, R₁₁ to R₁₆ and R₂₁ to R₂₆ are lower alkyl or lower alkoxy groups, R₁₇ and R₁₈ are groups selected from an N-lower-alkylpyridyl group, a lower-alkylammoniophenyl group, and an N-loweralkylimidazolyl group, and R₂₇ and R₂₈ indicate N-alkylammonio groups and one or more of metal [5,10,15,20-tetrakis (2-methylpyridyl) porphyrin] (MT2MPyP), metal [5,10,15,20-tetrakis (4-methylpyridyl) porphyrin] (MT4MPyP), or metal [[1,3,5,8-tetramethyl-2,4-divinyl-6,7-di (4-methylpyridylamideethyl)] porphyrin] (MPPIX-DMPyAm), wherein the metal (M) is iron (Fe), manganese (Mn), cobalt (Co), copper (Cu), molybdenum (Mo), chromium (Cr), or iridium (Ir), and the niosome-forming substance is a nonionic surfactant or a mixture of a nonionic surfactant and a cholesterol or a triacylglycerol.

30 (New): The metalloporphyrin complex-embedding niosome of claim 20, wherein at least one of R₁ to R₄ is a group selected from an N-lower-alkylpyridyl group, a lower-alkylammoniophenyl group, and an N-lower-alkylimidazolyl group, R₁₁ to R₁₆ and R₂₁ to R₂₆ are lower alkyl or lower alkoxy groups, R₁₇ and R₁₈ are groups selected from an N-lower-alkylpyridyl group, a lower-alkylammoniophenyl group, and an N-loweralkylimidazolyl group, and R₂₇ and R₂₈ indicate N-alkylammonio groups and one or more of metal [5,10,15,20-tetrakis (2-methylpyridyl) porphyrin] (MT2MPyP), metal [5,10,15,20-tetrakis (4-methylpyridyl) porphyrin] (MT4MPyP), or metal [[1,3,5,8-tetramethyl-2,4-divinyl-6,7-di (4-methylpyridylamideethyl)] porphyrin] (MPPIX-DMPyAm),

wherein the metal (M) is iron (Fe), manganese (Mn), cobalt (Co), copper (Cu), molybdenum (Mo), chromium (Cr), or iridium (Ir), and

the niosome is endoplasmic reticula with a diameter of 100 nm or less.

31 (New): The metalloporphyrin complex-embedding niosome of claim 20, wherein R_{27} and R_{28} are N-alkylammonio groups and one or more of metal [5,10,15,20-tetrakis (2-methylpyridyl) porphyrin] (MT2MPyP), metal [5,10,15,20-tetrakis (4-methylpyridyl) porphyrin] (MT4MPyP), or metal [[1,3,5,8-tetramethyl-2,4-divinyl-6,7-di (4-methylpyridylamideethyl)]porphyrin] (MPPIX-DMPyAm),

wherein the metal (M) is iron (Fe), manganese (Mn), cobalt (Co), copper (Cu), molybdenum (Mo), chromium (Cr), or iridium (Ir),

the niosome-forming substance is a nonionic surfactant or a mixture of a nonionic surfactant and a cholesterol or a triacylglycerol, and

the niosome is endoplasmic reticula with a diameter of 100 nm or less.

32 (New): A composition comprising the metalloporphyrin complex-embedding niosome of claim 20 and a pharmaceutically acceptable carrier or excipient.


33 (New): A method for treating a subject having cancer, comprising administering the composition according to claim 32 to said subject.

34 (New): A method for treating a disorder brought about by active oxygen species comprising administering the composition according to claim 32 to a subject in thereof.

35 (New): A method for treating a disease or disorder selected from the group consisting of inflammation, nervous system diseases, arteriosclerosis, and diabetes comprising administering the composition of claim 32 to a subject in need thereof.

36 (New): A niosome embedding a cationized metalloporphyrin complex of formula (I), (II) or (III);

wherein formula (I), (II), and (III) are:



wherein

at least one of R₁ to R₄ is a group selected from an N-lower-alkylpyridyl group, a lower-alkylammoniophenyl group, and an N-lower-alkylimidazolyl group,

R₁₁ to R₁₆ and R₂₁ to R₂₆ are lower alkyl or lower alkoxy groups,

R₁₇ and R₁₈ are groups selected from an N-lower-alkylpyridyl group, a lower-alkylammoniophenyl group, and an N-loweralkylimidazolyl group, and

R₂₇ and R₂₈ are N-alkylammonio groups.

37 (New): The niosome of claim 36, which is prepared from a non-ionic surfactant, or a non-ionic surfactant and a cholesterol or triacylglycerol.